Coronavirus Infection - Pipeline Review, H1 2014

Coronavirus Infection - Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Coronavirus Infection - Pipeline Review, H1 2014’, provides an overview of the Coronavirus Infection’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Coronavirus Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Coronavirus Infection and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Coronavirus Infection
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Coronavirus Infection and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Coronavirus Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Coronavirus Infection pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Coronavirus Infection
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Coronavirus Infection pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Coronavirus Infection Overview 6
Therapeutics Development 7
Pipeline Products for Coronavirus Infection - Overview 7
Pipeline Products for Coronavirus Infection - Comparative Analysis 8
Coronavirus Infection - Therapeutics under Development by Companies 9
Coronavirus Infection - Therapeutics under Investigation by Universities/Institutes 10
Coronavirus Infection - Pipeline Products Glance 11
Early Stage Products 11
Coronavirus Infection - Products under Development by Companies 12
Coronavirus Infection - Products under Investigation by Universities/Institutes 13
Coronavirus Infection - Companies Involved in Therapeutics Development 14
Inovio Pharmaceuticals, Inc. 14
Novavax, Inc. 15
NanoViricides, Inc. 16
Synairgen plc 17
Coronavirus Infection - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Combination Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 25
Drug Profiles 27
interferon beta-1a - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Virus Protease Inhibitors For Viral Infections - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
MERS-CoV Vaccine - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
DNA Vaccine for MERS Coronavirus Infection - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
interferon alfa-2b + ribavirin - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Anti-MERS Coronavirus Program - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Enveloped Virus Vaccine - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Coronavirus Infection - Recent Pipeline Updates 35
Coronavirus Infection - Dormant Projects 37
Coronavirus Infection - Product Development Milestones 38
Featured News & Press Releases 38
Apr 30, 2014: New Experimental Vaccine Produces Immune Response Against Middle East Respiratory Syndrome Coronavirus 38
Appendix 39
Methodology 39
Coverage 39
Secondary Research 39
Primary Research 39
Expert Panel Validation 39
Contact Us 40
Disclaimer 40

List of Tables
Number of Products under Development for Coronavirus Infection, H1 2014 7
Number of Products under Development for Coronavirus Infection - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Number of Products under Investigation by Universities/Institutes, H1 2014 10
Comparative Analysis by Early Stage Development, H1 2014 11
Products under Development by Companies, H1 2014 12
Products under Investigation by Universities/Institutes, H1 2014 13
Coronavirus Infection - Pipeline by Inovio Pharmaceuticals, Inc., H1 2014 14
Coronavirus Infection - Pipeline by Novavax, Inc., H1 2014 15
Coronavirus Infection - Pipeline by NanoViricides, Inc., H1 2014 16
Coronavirus Infection - Pipeline by Synairgen plc, H1 2014 17
Assessment by Monotherapy Products, H1 2014 18
Assessment by Combination Products, H1 2014 19
Number of Products by Stage and Target, H1 2014 21
Number of Products by Stage and Mechanism of Action, H1 2014 23
Number of Products by Stage and Route of Administration, H1 2014 24
Number of Products by Stage and Molecule Type, H1 2014 26
Coronavirus Infection Therapeutics - Recent Pipeline Updates, H1 2014 35
Coronavirus Infection - Dormant Projects, H1 2014 37

List of Figures
Number of Products under Development for Coronavirus Infection, H1 2014 7
Number of Products under Development for Coronavirus Infection - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Number of Products under Investigation by Universities/Institutes, H1 2014 10
Comparative Analysis by Early Stage Products, H1 2014 11
Assessment by Monotherapy Products, H1 2014 18
Number of Products by Top 10 Target, H1 2014 20
Number of Products by Stage and Top 10 Target, H1 2014 21
Number of Products by Top 10 Mechanism of Action, H1 2014 22
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 23
Number of Products by Top 10 Molecule Type, H1 2014 25
Number of Products by Stage and Top 10 Molecule Type, H1 2014 26